Welcome to our dedicated page for STEMTECH CORPORATION news (Ticker: STEK), a resource for investors and traders seeking the latest updates and insights on STEMTECH CORPORATION stock.
Stemtech Corporation (OTCQB:STEK) generates news around its activities in stem cell nutrition, wellness, anti‑aging, and pet health. The company describes itself as a global leader and pioneer in stemceuticals™ – all‑natural, plant‑based nutraceutical products designed to support the body’s own regenerative processes. News updates often highlight how Stemtech advances its stem cell nutrition platform, expands distribution, and develops new product lines for both humans and pets.
Investors and observers following STEK news can expect coverage of product launches and enhancements, such as the RCM System (stemrelease3™, StemFlo® Advanced, MigraStem®), OraStem® Toothpaste, Cellect One® Shield: HOCL, Cellect One® Rapid Renew Stem Cell Peptide Night Cream, and the StemPets™ pet supplement line for dogs and cats. Company announcements also describe educational initiatives like the “Well‑Aging” video series hosted by Dr. Lizette Leos, MD, which discusses cellular regeneration, biohacking, and stem cell nutrition.
Stemtech’s news flow also includes international growth developments. Recent releases describe joint ventures for Stemtech HealthSciences India Pvt Ltd in partnership with Innoventure Dynamic LLP, plans for Stemtech Asia (Hong Kong) with Lightway Ventures to distribute products in China, and an exclusive licensing agreement with Energy International Development Co., Ltd. for Taiwan. Operational updates, such as resolving backorders of core stem cell nutrition products and manufacturing and distribution arrangements, are also part of the company’s communications.
Leadership and scientific updates feature prominently, including appointments such as the Chief Scientific Officer role for Dr. Lizette Leos and collaborations with clinicians like Dr. Sabine Hazan, MD, to design clinical trials on the RCM System. For readers tracking STEK, this news page offers a centralized view of Stemtech’s product, scientific, and international expansion announcements.
Stemtech Corporation (OTCQB: STEK) announced the Go-Live date for its Stemtech Advance Office on September 19, 2022. Developed with VERB Technology Company, Inc. (NASDAQ: VERB), the platform aims to enhance communication and business capabilities for Independent Business Partners (IBPs). President John W. Meyer highlighted the software's potential to improve recruiting and retention efforts, leveraging interactive video-based sales applications. Stemtech, known for its patent-protected nutraceutical products supporting adult stem cell release, is positioned to increase its market momentum through this strategic partnership.
Stemtech Corporation (OTCQB: STEK) announces the appointment of Professor Dr. Bankole Johnson to its Life Sciences Advisory Board. Dr. Johnson, a highly regarded figure in the medical field, is expected to provide valuable insights as Stemtech focuses on enhancing health through science. His extensive background includes roles at the University of Virginia and the University of Maryland, along with recognition for his work in addiction treatment. This addition aligns with Stemtech's strategy to advance its proprietary health products and strengthen its leadership.
Stemtech Corporation (OTCQB: STEK) has issued a Letter of Intent to acquire Life Factor Research, enhancing its R&D capabilities in stem cell nutrition and related products. This acquisition is expected to position Stemtech at the forefront of advanced stem cell technology, allowing quicker market penetration of innovative health products. The collaboration aims to cater to an expanding market with a focus on anti-aging and longevity. The CEO of Life Factor Research highlights the potential for redefining market standards through this partnership.
Stemtech Corporation (OTCQB: STEK), a leader in nutraceuticals, has announced its sponsorship of the ADVENT EXPO. This event aims to connect millions of viewers globally in a virtual metaverse setting, promoting Stemtech's anti-aging and plant-based stem cell nutrition products. President John W. Meyer emphasized the exposure opportunities provided by the Expo, which combines health and financial aspects for potential consumers. Stemtech's products, which are patented and all-natural, are produced under stringent manufacturing practices.
Stemtech Corporation (OTCQB: STEK) announced the trademark registration of OraStem®, its all-natural toothpaste, in Mexico. This registration signifies the company's commitment to protecting its intellectual property, benefiting its Independent Business Partners and customers. OraStem boasts 14 natural ingredients, providing anti-oxidative, anti-microbial protection, and supports oral health at a cellular level. The product's efficacy is backed by numerous peer-reviewed studies. Additionally, a new travel size of OraStem will launch soon, enhancing product accessibility.
Stemtech Corporation (OTCQB: STEK), a Florida-based nutraceutical company, announced the adoption of VERB's interactive video-based sales tools to enhance customer engagement and increase sales conversion rates. The platform includes verbCRM and verbLIVE, facilitating direct sales efforts by Independent Business Partners (IBPs). Stemtech, known for its patent-protected stem cell nutrition products, aims to empower its IBPs with advanced digital tools, leveraging social media for customer acquisition. This collaboration is expected to boost marketing effectiveness and sales performance.
Stemtech Corporation (OTCQB:STEK) announced the appointment of Izzy Matos as Founding Independent Business Partner. Matos, a key figure since the company's inception in 2005, previously developed the compensation plan and built a personal network of over 70,000 individuals. A graduate of the Network Marketing Hall of Fame, he aims to leverage this new role to enhance Stemtech's growth. The company, known for its patented stem cell nutrition products, has a strong history of recognition, having appeared on the Inc. 5000 Fastest-Growing Companies list multiple times.
Summary not available.
Stemtech Corporation (OTCQB:STEK) reported a 38% increase in independent business partner recruitment from April 1, 2022, to June 20, 2022, compared to the same period last year. This growth has positioned the company at 93rd in the Business For Home Momentum Ranks, improving by 174 places. Stemtech specializes in patent-protected nutraceutical products that enhance adult stem cell function. The company aims to expand further in the direct sales market, which represents $192 billion in annual sales.
Stemtech Corporation (OTCQB:STEK) announced that its Chairman and CEO, Charles Arnold, received the Global Eagles Business Leader of the Year award in Fort Lauderdale, Florida. This accolade recognizes Arnold's leadership in the nutraceutical sector and his contributions to international development. Stemtech, a pioneer in stem cell nutrition, specializes in patented products that enhance the release and migration of adult stem cells. The company aims to maintain growth and innovation while adhering to strict manufacturing standards.